Baxter Bros Inc. Purchases 213 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Baxter Bros Inc. grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 17.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,441 shares of the pharmaceutical company’s stock after purchasing an additional 213 shares during the quarter. Baxter Bros Inc.’s holdings in Vertex Pharmaceuticals were worth $642,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Notis McConarty Edward increased its position in shares of Vertex Pharmaceuticals by 1.5% during the 2nd quarter. Notis McConarty Edward now owns 7,381 shares of the pharmaceutical company’s stock valued at $3,286,000 after purchasing an additional 106 shares during the last quarter. Trifecta Capital Advisors LLC grew its position in Vertex Pharmaceuticals by 5.5% during the 2nd quarter. Trifecta Capital Advisors LLC now owns 15,340 shares of the pharmaceutical company’s stock worth $6,829,000 after acquiring an additional 802 shares during the last quarter. Maryland State Retirement & Pension System grew its position in Vertex Pharmaceuticals by 3.4% during the 2nd quarter. Maryland State Retirement & Pension System now owns 12,500 shares of the pharmaceutical company’s stock worth $5,565,000 after acquiring an additional 409 shares during the last quarter. Dempze Nancy E grew its position in Vertex Pharmaceuticals by 1.7% during the 2nd quarter. Dempze Nancy E now owns 7,180 shares of the pharmaceutical company’s stock worth $3,197,000 after acquiring an additional 117 shares during the last quarter. Finally, Dohj LLC bought a new position in Vertex Pharmaceuticals during the 2nd quarter worth approximately $422,000. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $421.15 on Thursday. The firm has a market cap of $107.98 billion, a P/E ratio of 30.10 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The business’s 50 day moving average price is $395.83 and its 200-day moving average price is $440.97.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same period last year, the company earned ($12.83) EPS. The business’s quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were bought at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the transaction, the director directly owned 45,000 shares of the company’s stock, valued at $17,535,600. This trade represents a 12.50% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on VRTX. Royal Bank Of Canada reduced their price target on Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating on the stock in a research report on Tuesday, August 5th. Stifel Nicolaus reduced their price target on Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating on the stock in a research report on Tuesday, August 5th. Cantor Fitzgerald reduced their price target on Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 5th. Morgan Stanley set a $439.00 price target on Vertex Pharmaceuticals and gave the stock an “equal weight” rating in a research report on Tuesday, August 5th. Finally, Scotiabank reduced their price target on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $494.43.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.